Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

<jats:title>ABSTRACT</jats:title> <jats:p>The MIC is an essential quantitative measure of the asexual blood-stage effect of an antimalarial drug. In areas of high malaria transmission, and thus frequent individual infection, patients who are treated with slowly eliminated antimalarials become reinfected as drug concentrations decline. In the frequent relapse forms of <jats:named-content content-type="genus-species">Plasmodium vivax</jats:named-content> and in <jats:named-content content-type="genus-species">Plasmodium ovale</jats:named-content> malaria, recurrent infection occurs from relapses which begin to emerge from the liver approximately 2 weeks after the primary illness. An important determinant of the interval from starting treatment of a symptomatic infection to the patency of these recurrent infections is the <jats:italic>in vivo</jats:italic> concentration-response relationship and thus the <jats:italic>in vivo</jats:italic> MIC. Using mechanistic knowledge of parasite asexual replication and the pharmacokinetic and pharmacodynamic properties of the antimalarial drugs, a generative statistical model was derived which relates the concentration-response relationship to time of reinfection patency. This model was used to estimate the <jats:italic>in vivo</jats:italic> MIC of chloroquine in the treatment of <jats:named-content content-type="genus-species">Plasmodium vivax</jats:named-content> malaria.</jats:p>

Original publication

DOI

10.1128/aac.02476-17

Type

Journal article

Journal

Antimicrobial Agents and Chemotherapy

Publisher

American Society for Microbiology

Publication Date

16/04/2018

Volume

62

Pages

e02476 - 17